GuidelineBlood advances2018
American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.
Guideline in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 312 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
312 citing papers in PubMed, 4 syntheses or guidelines pooled it, 684 citations in OpenAlex.
- Direct Oral Anticoagulants as Primary or Secondary Treatment for Heparin-Induced Thrombocytopenia (HIT) and Associated Thromboembolism (HITT)-A Meta-Analysis.European journal of haematology · 2026Pooled it
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Safety and efficacy of fondaparinux use in hemodialysis patients with heparin-induced thrombocytopenia: a systematic review.European journal of clinical pharmacology · 2025Pooled it
- A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines.Journal of thrombosis and thrombolysis · 2022Pooled it
- Anticoagulation in Mechanical Circulatory Support: Contemporary Challenges and Future Directions in Cardiovascular Pharmacotherapy.Cardiology and therapy · 2026Review
- Neutrophil-Mediated Platelet Phagocytosis: Implications of Anticoagulant Additives in Blood Collection Tubes for the Diagnosis of HIT.International journal of laboratory hematology · 2026Article
- Real-World Performance of the STic Expert HIT Kit and the Diagnostic Dilemma of Borderline Results in Heparin Induced Thrombocytopenia.International journal of laboratory hematology · 2026Article
- CIRSE Standards of Practice for the Endovascular Management of Acute Lower Limb Ischaemia.Cardiovascular and interventional radiology · 2026Article
- Unfractionated Heparin and Low-Molecular-Weight Heparin in Sepsis: Anti-Inflammatory and Anticoagulant Effects Versus No Anticoagulation-A Propensity Score-Matched Analysis.Journal of clinical laboratory analysis · 2026Article
- Transcatheter Edge-to-Edge Repair Under Argatroban in IABP-Supported Acute Mitral Regurgitation With Suspected Heparin-Induced Thrombocytopenia.JACC. Case reports · 2026Article
- When Coronary Thrombosis Outpaces Technical Success.JACC. Case reports · 2026Article
- Unmasking Essential Thrombocythemia in Heparin-Induced Thrombocytopenia After Coronary Artery Bypass Grafting.JACC. Case reports · 2026Article
- Rescue Veno-Venous Extracorporeal Membrane Oxygenation for Aspiration-Induced Refractory Hypoxaemia Before Non-Deferrable Abdominal Surgery: A Case Report.Journal of clinical medicine · 2026Article
- ASH clinical practice guidelines: evaluation of discordance between certainty of evidence and strength of recommendations.Blood advances · 2026Article
- Fulminant Thromboinflammatory Syndrome Following an Influenza-like Illness in an Adolescent: Clinical Insights from a Case Report.International journal of molecular sciences · 2026Article
- [Clinical characteristics, diagnosis, and treatment of 40 cases of venous thrombotic disease in children at a single center].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Article
- Pathogenic PF4/Polyanion ELISA-Negative Antibodies in HIT.American journal of hematology · 2026Article
- Evaluation of anticoagulation management in patients with suspected heparin-induced thrombocytopenia awaiting diagnosis confirmation.Journal of thrombosis and thrombolysis · 2026Article
- Comparative efficacy and safety of anticoagulation strategies in continuous renal replacement therapy: a real-world cohort study.BMC nephrology · 2026Article
- Evaluation of argatroban to warfarin transition process in heparin-induced thrombocytopenia.Journal of thrombosis and thrombolysis · 2026Article
252 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 5 countries.
Funding
Abstract
backgroundHeparin-induced thrombocytopenia (HIT) is an adverse drug reaction mediated by platelet-activating antibodies that target complexes of platelet factor 4 and heparin. Patients are at markedly increased risk of thromboembolism.
objectiveThese evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about diagnosis and management of HIT.
methodsASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations, which were subject to public comment.
resultsThe panel agreed on 33 recommendations. The recommendations address screening of asymptomatic patients for HIT, diagnosis and initial management of patients with suspected HIT, treatment of acute HIT, and special situations in patients with acute HIT or a history of HIT, including cardiovascular surgery, percutaneous cardiovascular intervention, renal replacement therapy, and venous thromboembolism prophylaxis.
conclusionsStrong recommendations include use of the 4Ts score rather than a gestalt approach for estimating the pretest probability of HIT and avoidance of HIT laboratory testing and empiric treatment of HIT in patients with a low-probability 4Ts score. Conditional recommendations include the choice among non-heparin anticoagulants (argatroban, bivalirudin, danaparoid, fondaparinux, direct oral anticoagulants) for treatment of acute HIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.